OXIS INTERNATIONAL, INC. (Pink Sheets: OXIS, Paris: OXI) announced today that the Company has retained Quinn Emanuel Urquhart Oliver & Hedges (“Quinn Emanuel”) to enforce all patents related to the unique benefits of its potent antioxidant compound L-Ergothioneine (“ERGO”).

Mr. Tony Cataldo, Chairman and Chief Executive Officer of Oxis, stated, “Oxis holds patents and patent applications on the benefits of ERGO as a significant combater of oxidative stress within the body. We have significant research that demonstrate ERGO’s highly beneficial effects on the reduction in oxidative stress and we intend to pursue opportunities in the consumer market and have begun test marketing of products and through the recent financing have the financial resources to scale to full production launch in the near future.”

“We intend to vigorously defend our patents against any potential infringer no matter how large or small they may be. Quinn Emanuel is the pre-eminent law firm in business litigation having won the most cases and the largest settlements of any law firm and ranked #1 in business litigation in the US. It has won over $10 billion in judgments and settlements, several of which have been for nine figures. We are proud to have them as part of the Oxis team and we are confident that potential infringers will think twice before doing so knowing that with Quinn Emanuel is on our side,” Mr. Cataldo concluded.

Contact the Company at: 310-860-5184 for additional information about OXIS, or visit our web site: www.oxis.com.

Forward-Looking StatementThis press release contains forward-looking statements that involve numerous risks and uncertainties. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Company’s filings with the Securities and Exchange Commission.

About OXIS International, Inc.

OXIS International, Inc. focuses on the research, development and marketing of nutraceutical products in the field of oxidative stress reduction. Many of our planned nutraceutical products include L-Ergothioneine (“ERGO”) as a component. The Company holds patents and patent applications for the protective effect of ERGO on mitochondria, the commercial preparation process and the neuroprotective effects of ERGO. OXIS believes that there is a high potential to sell ERGO as a food supplement or in the form of tablets and is pursuing this avenue of sales and distribution of ERGO.

About Quinn Emanuel Urquhart Oliver & Hedges, LLP (“Quinn Emanuel”)

Quinn Emanuel is a 400+ lawyer business litigation firm - the largest in the United States devoted solely to business litigation. Its lawyers have tried 1297 cases and won 1186, or 91.4%. When representing defendants, its trial experience garnered it better settlements or defense verdicts. When representing plaintiffs, its lawyers have won over $10 billion in judgments and settlements. It is the only firm in the United States that has won four nine-figure jury verdicts in the last seven years. It has also obtained four nine-figure and two ten-figure settlements in the same period.

GT Biopharma (TG:OXI)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more GT Biopharma Charts.
GT Biopharma (TG:OXI)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more GT Biopharma Charts.